Cyfuse Closes JPY422 Million (US$4.8 Million) Series A Financing

Tokyo, JAPAN – January 23, 2013 – Cyfuse Biomedical K.K., a Tokyo-based company which develops and commercializes Cell-Based Products and an automated “Scaffold-Free 3D Bio Fabrication System” with its partners, announced today that it has closed a JPY422 Million (US$4.8 Million) Series A – financing including 4 institutional investors led by The University of Tokyo Edge Capital (UTEC: Managing Partner & President – Tomotaka Goji), and followed by NISSAY CAPITAL Co.,ltd. (NCC: Representative Director – Eiji Arima), Nippon Venture Capital Co., Ltd. (NVCC: President – Shuichi Okuhara), and Industrial Growth Platform, Inc. (IGPI: Representative Director & CEO – Kazuhiko Toyama).
The funding will be used for the forgoing clinical development of its cartilage regeneration technology and to further accelerate the use deployment of its proprietary platform technology.

About Cyfuse Biomedical K.K.

Cyfuse Biomedical K.K. (Headquarters: Chiyoda-Ku Tokyo, CEO – Koji KUCHIISHI) is a regenerative medicine technology startup focused on developing and commercializing globally its proprietary Cell-Based Products and 3D BioFabrication system. Its platform technology, which is capable of generating a much thicker and more elastic tissue than any other existing technology, will be further expected to become a technology breakthrough that should enable artificial internal organs and many other regenerative medicine.
The company, along with its strategic partner Shibuya Kogyo Co., Ltd. (Headquarters: Kanazawa-shi, Ishikawa prefecture JAPAN, CEO Hirotoshi Shibuya), also developed successfully a robotic system which automatically assembles spheroids (cell aggregates) into any desired 3D shapes. The system is capable of quickly generating a 3D tissue structure from 3D modeling data and cells provided. The company has successfully begun selling the system to major R&D institutes including universities etc.
Also, the 3D Stem Cell product, its forgoing development pipeline, is highly expected to deliver a new ground-breaking cure for osteoarthrosis patients, who are considered in general to have no effective cures except using the traditional artificial joints, by using its technology which regenerates both the damaged cartilage and the underlying subchondral bones simultaneously. The technology was selected and granted a research fund in 2010 from Japan New Energy and Industrial Technology Development Organization (NEDO), and the company has been working jointly with Kyushu University for the development.
The funding will be used for the forgoing clinical development of its cartilage regeneration technology and to accelerate the use deployment of its proprietary platform technology towards other applications of tissues/organs.

【Company】 Cyfuse Biomedical K.K.
【Headquarters】 Kanda Nishiki-cho 3-21-1055, Chiyoda-Ku Tokyo, 101-0054 Japan
【URL】 www.cyfusebio.com
【Founded】 11 August 2010
【CEO and president, co-founder】 Koji KUCHIISHI
【Capital】 JPY212.625 Million
【Fiscal Year End】 December
【Principal Business】 Sale of robotic systems capable of assembling cell aggregates into 3D layouts; R&D and licensing of Scaffold-Free 3D tissue products.
【Co-R&D Labs】 Kyushu University, Saga University, Kyoto University, Yokohama City University, Tokyo University